CD274 and non-small cell lung carcinoma: In 2017, the KEYNOTE-598 phase III randomized, double-blind study aimed to test whether ipilimumab might improve the efficacy of pembrolizumab, which is a standard first-line therapy for metastatic NSCLC patients with PD-L1 TPS > 50% [251].